The expression of c-Met pathway components in unclassified pleomorphic sarcoma/malignant fibrous histiocytoma (UPS/MFH): A tissue microarray study

Histopathology

Volumn 59, Issue 3, 2011, Pages 556-561

  Lahat, Guy ^a   Zhang, Pingyu ^a   Zhu, Quan Sheng ^a   Torres, Keila ^a   Ghadimi, Markus ^a   Smith, Kerrington D ^a   Wang, Wei Lien ^a   Lazar, Alexander J ^a,b   Lev, Dina ^a,b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

C Met; MEK; Molecular markers; Staging; Targeted therapy; UPS MFH

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ADULT; AGE; ARTICLE; CANCER INVASION; CANCER LOCALIZATION; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT FIBROUS HISTIOCYTOMA; MICROARRAY ANALYSIS; PLEOMORPHIC SARCOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SARCOMA; SEX DIFFERENCE; TISSUE MICROARRAY;

HISTIOCYTOMA, MALIGNANT FIBROUS; HUMANS; IMMUNOHISTOCHEMISTRY; MAP KINASE KINASE KINASES; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-MET; SOFT TISSUE NEOPLASMS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053312080     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2011.03946.x     Document Type: Article

References (35)

1. Ozzello L, Stout AP, Murray MR. Cultural characteristics of malignant histiocytomas and fibrous xanthomas. Cancer 1963; 16; 331-344.
2. Weiss SW, Enzinger FM. Malignant fibrous histiocytoma: an analysis of 200 cases. Cancer 1978; 41; 2250-2266.
3. Weiss SW, Enzinger FM. Myxoid variant of malignant fibrous histiocytoma. Cancer 1977; 39; 1672-1685.
4. Fletcher CD. Pleomorphic malignant fibrous histiocytoma: fact or fiction? A critical reappraisal based on 159 tumors diagnosed as pleomorphic sarcoma. Am. J. Surg. Pathol. 1992; 16; 213-228.
5. Fletcher CD, Gustafson P, Rydholm A, Willen H, Akerman M. Clinicopathologic re-evaluation of 100 malignant fibrous histiocytomas: prognostic relevance of subclassification. J. Clin. Oncol. 2001; 19; 3045-3050.
6. Fletcher CD. The evolving classification of soft tissue tumours: an update based on the new WHO classification. Histopathology 2006; 48; 3-12.
7. Hollowood K, Fletcher CD. Malignant fibrous histiocytoma: morphologic pattern or pathologic entity? Semin. Diagn. Pathol. 1995; 12; 210-220.
8. McCormick D, Mentzel T, Beham A, Fletcher CD. Dedifferentiated liposarcoma. Clinicopathologic analysis of 32 cases suggesting a better prognostic subgroup among pleomorphic sarcomas. Am. J. Surg. Pathol. 1994; 18; 1213-1223.
9. Mentzel T, Calonje E, Fletcher CD. Leiomyosarcoma with prominent osteoclast-like giant cells. Analysis of eight cases closely mimicking the so-called giant cell variant of malignant fibrous histiocytoma. Am. J. Surg. Pathol. 1994; 18; 258-265.
10. Fletcher CD. Malignant fibrous histiocytoma? Histopathology 1987; 11; 433-437.
11. Fletcher CDM, Unni K, Mertens F eds. Pathology and genetics of tumors of soft tissue and bone. World Health Organization classification of tumours. Lyon: ARC Press, 2002.
12. Fabbro D, Ruetz S, Buchdunger E et al. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Ther. 2002; 93; 79-98.
13. Boyle WJ. Growth factors and tyrosine kinase receptors during development and cancer. Curr. Opin. Oncol. 1992; 4; 156-162.
14. Sioud M, Leirdal M. Druggable signaling proteins. Methods Mol. Biol. 2007; 361; 1-24.
15. Ansari J, Palmer DH, Rea DW, Hussain SA. Role of tyrosine kinase inhibitors in lung cancer. Anticancer Agents Med. Chem. 2009; 9; 569-575.
16. Haddad R, Lipson KE, Webb CP. Hepatocyte growth factor expression in human cancer and therapy with specific inhibitors. Anticancer Res. 2001; 21; 4243-4252.
17. Jeffers M, Rong S, Woude GF. Hepatocyte growth factor/scatter factor-Met signaling in tumorigenicity and invasion/metastasis. J. Mol. Med. 1996; 74; 505-513.
18. Jankowski K, Kucia M, Wysoczynski M et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003; 63; 7926-7935.
19. Kuhnen C, Tolnay E, Steinau HU, Voss B, Muller KM. Expression of c-Met receptor and hepatocyte growth factor/scatter factor in synovial sarcoma and epithelioid sarcoma. Virchows Arch. 1998; 432; 337-342.
20. Wallenius V, Hisaoka M, Helou K et al. Overexpression of the hepatocyte growth factor (HGF) receptor (Met) and presence of a truncated and activated intracellular HGF receptor fragment in locally aggressive/malignant human musculoskeletal tumors. Am. J. Pathol. 2000; 156; 821-829.
21. Fukuda T, Ichimura E, Shinozaki T et al. Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol. Int. 1998; 48; 757-762.
22. Rees H, Williamson D, Papanastasiou A et al. The MET receptor tyrosine kinase contributes to invasive tumour growth in rhabdomyosarcomas. Growth Factors 2006; 24; 197-208.
23. Lazar AJ, Das P, Tuvin D et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin. Cancer Res. 2007; 13; 7314-7321.
24. Lazar AJ, Lahat G, Myers SE et al. Validation of potential therapeutic targets in alveolar soft part sarcoma: an immunohistochemical study utilizing tissue microarray. Histopathology 2009; 55; 750-755.
25. Tsuda M, Davis IJ, Argani P et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007; 67; 919-929.
26. Stockwin LH, Vistica DT, Kenney S et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer 2009; 9; 22.
27. Yamamoto T, Marui T, Akisue T et al. Coexpression of hepatocyte growth factor and its receptor c-Met correlates with high MIB-1 proliferative index in malignant fibrous histiocytoma. Pathol. Res. Pract. 2004; 200; 397-402.
28. Lahat G, Tuvin D, Wei C et al. Molecular prognosticators of complex karyotype soft tissue sarcoma outcome: a tissue microarray-based study. Ann. Oncol. 2010; 21; 1112-1120.
29. Mito JK, Riedel RF, Dodd L et al. Cross species genomic analysis identifies a mouse model as undifferentiated pleomorphic sarcoma/malignant fibrous histiocytoma. PLoS ONE 2009; 4; e8075.
30. Hassan S, Ferrario C, Mamo A, Basik M. Tissue microarrays: emerging standard for biomarker validation. Curr. Opin. Biotechnol. 2008; 19; 19-25.
31. Voduc D, Kenney C, Nielsen TO. Tissue microarrays in clinical oncology. Semin. Radiat. Oncol. 2008; 18; 89-97.
32. Rubin JS, Bottaro DP, Aaronson SA. Hepatocyte growth factor/scatter factor and its receptor, the c-met proto-oncogene product. Biochim. Biophys. Acta 1993; 1155; 357-371.
33. Weidner KM, Di Cesare S, Sachs M, Brinkmann V, Behrens J, Birchmeier W. Interaction between Gab1 and the c-Met receptor tyrosine kinase is responsible for epithelial morphogenesis. Nature 1996; 384; 173-176.
34. McCubrey JA, Steelman LS, Chappell WH et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim. Biophys. Acta 2007; 1773; 1263-1284.
35. McCubrey JA, Steelman LS, Abrams SL et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv. Enzyme Regul. 2006; 46; 249-279.